The Effect of Magnesium Oxide on Plasma Phosphate in Hemodialysis Patients

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01854437

Enrollment

Registered

2013-05-15

Start date

2012-06-30

Completion date

2012-12-31

Last updated

2013-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hyperphosphatemia

Keywords

mg oxide, hyperphosphatemia, plasma phosphor level

Brief summary

Hyperphosphatemia is a common problem in hemodialysis (HD) patients. Different chelators for control of Hyperphosphatemia are used. The aim of this study was to assess the effect of magnesium oxide (Mg Oxide) on the control of serum phosphorus (P) level and evaluation of its side effects in hemodialysis patients.

Interventions

DRUGMg Oxide

250 mg orally for 4 weeks

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 80 Years

Healthy volunteers

Yes

Inclusion criteria

hemodialysis with duration\>3 months serum P level \>5.5 mg/dl serum Ca\>8 mg/dl.

Exclusion criteria

Mg level \>3 mg/dl

Design outcomes

Primary

Measure	Time frame
plasma phosphate level	4 week

Countries

Iran

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026